Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis
This work describes the experience using T-VEC in melanoma at a single institution and highlights the presence of TERT promotor mutations as a possible driver of clinical response.
Authors
- Genevieve Marie Boland (ORCID: https://orcid.org/0000-0002-7522-6173)
- Sonia Cohen (ORCID: https://orcid.org/0000-0003-0172-5620)
- Kailan Sierra-Davidson (ORCID: https://orcid.org/0000-0001-8265-8620)
- Tanya Sharova
- Aikaterini Dedeilia (ORCID: https://orcid.org/0000-0001-9429-246X)
- Aleigha Lawless (ORCID: https://orcid.org/0009-0009-3861-3164)
- Howard L. Kaufman (ORCID: https://orcid.org/0000-0003-3538-4166)
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1245/s10434-024-16346-x
- Citations
- 3
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.65
Funders
- U.S. Department of Defense
- Melanoma Research Alliance
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Harvard Catalyst
- Castle Biosciences
- National Institutes of Health
- National Center for Advancing Translational Sciences